| 4.49 0.05 (1.13%) | 04-17 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 5.31 | 1-year : | 6.2 |
| Resists | First : | 4.55 | Second : | 5.31 |
| Pivot price | 4.29 |
|||
| Supports | First : | 4.06 | Second : | 3.75 |
| MAs | MA(5) : | 4.46 | MA(20) : | 4.22 |
| MA(100) : | 4.28 |
MA(250) : | 4.16  |
|
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 90.2 | D(3) : | 90.1 |
| RSI | RSI(14): 58.6 |
|||
| 52-week | High : | 5.92 | Low : | 3.02 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ SRTS ] has closed below upper band by 27.5%. Bollinger Bands are 9% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 4.51 - 4.53 | 4.53 - 4.55 |
| Low: | 4.15 - 4.18 | 4.18 - 4.21 |
| Close: | 4.44 - 4.49 | 4.49 - 4.53 |
Sensus Healthcare, Inc., a medical device company, manufactures and sells radiation therapy devices to healthcare providers worldwide. The company uses superficial radiation therapy (SRT), a low-energy X-ray technology in its portfolio of treatment devices. It offers SRT-100, a photon X-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating non-melanoma skin cancers, including basal cell and squamous cell skin cancers, as well as other skin conditions, such as keloids; and SRT-100 Vision, which provides the user with a SRT-tailored treatment planning application that integrates the embedded high frequency ultrasound imaging module, volumetric tumor analysis, beam margins planning, and dosimetry parameters. The company also provides SRT-100 Plus; Sentinel service program, which offers its customers protection for their systems; and in-office laser rental services. In addition, it sells disposable lead shielding replacements; and disposable radiation safety items, such as aprons and eye shields, ultrasound probe film, and disposable applicator tips to treat various sized lesions and various areas of the body. Sensus Healthcare, Inc. was incorporated in 2010 and is headquartered in Boca Raton, Florida.
Sat, 11 Apr 2026
Q2 2025 Sensus Healthcare Inc Earnings Call Transcript - GuruFocus
Wed, 04 Mar 2026
Sensus Healthcare Inc. (SRTS) Stock Falls on Q4 2025 Earnings - Quiver Quantitative
Thu, 26 Feb 2026
Sachetta Eric buys Sensus Healthcare (SRTS) shares worth $7,620 - Investing.com
Sun, 15 Feb 2026
Sensus Healthcare, Inc. (NASDAQ:SRTS) Just Reported And Analysts Have Been Cutting Their Estimates - simplywall.st
Thu, 12 Feb 2026
Earnings call transcript: Sensus Healthcare’s Q4 2025 earnings miss forecasts - Investing.com
Thu, 12 Feb 2026
Sensus Healthcare Reports Fourth Quarter 2025 Financial Results - TradingView — Track All Markets
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Devices
|
|
| Shares Out | 16 (M) |
| Shares Float | 14 (M) |
| Held by Insiders | 18.2 (%) |
| Held by Institutions | 29.7 (%) |
| Shares Short | 395 (K) |
| Shares Short P.Month | 514 (K) |
| EPS | -0.47 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1.57 |
| Profit Margin | -28.1 % |
| Operating Margin | 40.8 % |
| Return on Assets (ttm) | -11.2 % |
| Return on Equity (ttm) | -14.9 % |
| Qtrly Rev. Growth | 155.6 % |
| Gross Profit (p.s.) | 0.72 |
| Sales Per Share | 1.66 |
| EBITDA (p.s.) | -0.61 |
| Qtrly Earnings Growth | 433.2 % |
| Operating Cash Flow | 1 (M) |
| Levered Free Cash Flow | 4 (M) |
| PE Ratio | -9.56 |
| PEG Ratio | 0 |
| Price to Book value | 2.85 |
| Price to Sales | 2.68 |
| Price to Cash Flow | 139.97 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|